<DOC>
	<DOC>NCT01150097</DOC>
	<brief_summary>The reason for this extension is to evaluate the long-term safety and efficacy of two concentration-controlled everolimus regimen in de novo liver transplant recipients. The most important long-term safety assessments include evaluation of renal function, progression of HCV related allograft fibrosis, and other treatment related effects at Month 36 post-transplantation compared to extension baseline (Months 24 post-transplantation).</brief_summary>
	<brief_title>Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Written informed consent Ability and willingness to adhere to study regimen Completed core study with assigned regimen; Patients fulfilling any of the following criteria are not eligible for inclusion in this study: Severe hypercholesterolemia or hypertriglyceridemia. Low platelet count. Low white blood cell count. Positive test for human immunodeficiency virus (HIV). Systemic infection requiring active use of IV antibiotics. Patients in a critical care setting. Use of prohibited medication. Use of immunosuppressive agents not utilized in the protocol. Hypersensitivity to any of the study drugs or similar drugs. Pregnant or nursing (lactating) women Women of childbearing potential not using a highly effective method of birth control. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Calcineurin inhibitors</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Renal function</keyword>
	<keyword>Progression of HCV related allograft fibrosis</keyword>
</DOC>